Workflow
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
ALPNAlpine Immune Sciences(ALPN) InvestorPlace·2024-04-11 13:47

Drug maker Alpine Immune Sciences (NASDAQ:ALPN) got a 4.9billionbuyoutofferfromVertexPharmaceuticals(NASDAQ:VRTX)aftergettinggoodnewsonanewdrug.Povetacicept,anautoimmunedrug,wonasuccessfulPhase2reviewfromtheFoodandDrugAdministration(FDA)fortreatingararekidneydiseaseandwillgointoPhase3trial.Alpinestockrose214.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ:VRTX) after getting good news on a new drug.Povetacicept, an autoimmune drug, won a successful Phase 2 review from the Food and Drug Administration (FDA) for treating a rare kidney disease and will go into Phase 3 trial. Alpine stock rose 21% on April 10, and another 36% overnight, opening April 11 at 64.18 per share. More Than Kidneys?While Povetacicept is only being tested for a rare kidney ...